Abstract 320P
Background
Ovarian cancer is 3rd most common malignancy in Indian women and 8th common cause of cancer related death in India. The aim for this study was to evaluate clinicopathological factors, patterns of treatment, progression free survival (PFS) and overall survival (OS) in Indian patients with advanced ovarian cancer.
Methods
This is a retrospective analysis of patients with stage III-IV ovarian cancer treated at HCG Cancer Center, Ahmedabad from June 2018- March 2023. Patients were identified using the institutional tumor registry and medical records and data was collected.
Results
Out of total 94 patients identified; 79 patients were eligible for further analysis. Median age was 55 years (range 29 to 76 years). 62 (78%) patients had stage III (IIIA-5,IIIB-3, IIIc-44) & 17 (22%) had stage IV (IVA-10, IVB-7). Most common histology was high grade serous carcinoma in 76 (96%) patients. Majority of patients received neoadjuvant chemotherapy followed by interim cytoreductive surgery (CRS), [61 patients (78%)] whereas 18 patients (22 %) underwent upfront surgery. Median duration of neoadjuvant chemotherapy was 3 months. 21 (26.57%) patients were treated with hyperthermic intraperitoneal chemotherapy (HIPEC). 60 patients (76%) received maintenance therapy [43 patients bevacizumab, 10 patients PARP (poly ADP ribose polymerase) inhibitor and 6 patients received both]. 33 patients (41%) developed recurrence among which 32 received further chemotherapy. In recurrent setting, patients received a median 3 lines of systemic therapy (range 0-5). Genetic testing was offered to all patients at the time of diagnosis, but only 36 (45%) patients opted for it. BRCA1 mutation was detected in 8 patients (22.2%), BRCA2 mutation in 4 (11%). Median follow up was 17 months. Median PFS was 20 months with 95% CI (16-22) & Median OS was not reached, 5-year OS was 32.1%.
Conclusions
Median PFS and OS in advanced ovarian cancer at our institute is comparable to global standards. With the availability of biosimilars and genetic testing, more patients are able to access maintenance therapies. Hopefully more patients can access standard of care therapies which will help close the gap between less developed and developed countries in terms of long term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract